Stockscreener 앱 받기
38.06
1.58%
-0.61
시간 외 거래:
38.00
-0.06
-0.16%
전일 마감가:
$38.67
열려 있는:
$37.55
하루 거래량:
4.53M
Relative Volume:
1.67
시가총액:
$10.25B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
21.50
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
-4.83%
1개월 성능:
-5.06%
6개월 성능:
-3.89%
1년 성능:
+11.55%
1일 변동 폭
$36.00
$38.41
1주일 범위
$36.00
$40.62
52주 변동 폭
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.06 | 10.41B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis Shares Fall After Guggenheim Downgrade - MarketScreener
EXEL Downgraded to Neutral by Guggenheim on November 3, 2025 | E - GuruFocus
Can Exelixis Inc. stock weather global recessionWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com
Real time alert setup for Exelixis Inc. performanceM&A Rumor & Weekly High Conviction Ideas - newser.com
Will Exelixis Inc. (EX9) stock rise with strong economyQuarterly Profit Report & Real-Time Volume Analysis Alerts - newser.com
Guggenheim Downgrades Exelixis to Neutral From Buy - MarketScreener
How Exelixis Inc. (EX9) stock reacts to Fed tightening2025 Buyback Activity & Expert Approved Trade Ideas - newser.com
How to escape a deep drawdown in Exelixis Inc.July 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
Exelixis Inc. stock trend forecast2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
How Exelixis Inc. stock trades before earningsIPO Watch & Weekly Watchlist for Hot Stocks - newser.com
Can you recover from losses in Exelixis Inc.Market Growth Summary & Daily Chart Pattern Signals - newser.com
Can Exelixis Inc. stock beat market expectations this quarterJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
Understanding Exelixis Inc.’s price movement2025 Market Sentiment & Weekly Stock Breakout Alerts - newser.com
How Exelixis Inc. (EX9) stock reacts to monetary easing2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Using data filters to optimize entry into Exelixis Inc.July 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction - Investing.com Nigeria
Why Exelixis Inc. is moving todayMarket Trend Summary & Daily Momentum Trading Reports - newser.com
Why Exelixis Inc. stock could benefit from AI revolutionEarnings Beat & AI Optimized Trade Strategies - newser.com
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Analyst Calls & Growth Focused Entry Reports - newser.com
How Exelixis Inc. stock trades during market volatilityQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Will Exelixis Inc. benefit from macro trends2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction By Investing.com - Investing.com South Africa
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth By Investing.com - Investing.com Philippines
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth - Investing.com
Key metrics from Exelixis Inc.’s quarterly data2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
Is Exelixis Inc. stock cheap at current valuation2025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
What recovery options are there for Exelixis Inc.Quarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
Exelixis Inc expected to post earnings of 61 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Exelixis Inc Stock Analysis and ForecastStock Market Trends & Small Investment Growth Plans - earlytimes.in
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data - AOL.com
Using RSI to spot recovery in Exelixis Inc.Layoff News & Weekly Momentum Stock Picks - newser.com
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewswire Inc.
Best data tools to analyze Exelixis Inc. stock2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
How Exelixis Inc. (EX9) stock reacts to new regulationsMarket Risk Analysis & High Accuracy Swing Entry Alerts - newser.com
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):